Meeder Asset Management Inc. grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1,222.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,609 shares of the biopharmaceutical company’s stock after purchasing an additional 3,336 shares during the quarter. Meeder Asset Management Inc.’s holdings in ACADIA Pharmaceuticals were worth $57,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in ACADIA Pharmaceuticals by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 8,829,618 shares of the biopharmaceutical company’s stock worth $183,303,000 after acquiring an additional 155,172 shares during the last quarter. Macquarie Group Ltd. bought a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth $2,345,000. Peregrine Capital Management LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth $15,639,000. Renaissance Technologies LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth $3,408,000. Finally, GSA Capital Partners LLP bought a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth $243,000. Hedge funds and other institutional investors own 95.20% of the company’s stock.
A number of equities research analysts have recently commented on the company. Cantor Fitzgerald lifted their target price on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 1st. Leerink Swann began coverage on ACADIA Pharmaceuticals in a research note on Monday, November 12th. They issued a “market perform” rating and a $21.00 price objective on the stock. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $25.00 price objective on the stock in a research note on Thursday, January 17th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 1st. Finally, BidaskClub cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.09.
In other news, Director Bros. Advisors Lp Baker bought 11,764,705 shares of the company’s stock in a transaction on Friday, November 30th. The shares were acquired at an average cost of $17.00 per share, with a total value of $199,999,985.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Brege sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 9th. The stock was sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $200,000. The disclosure for this sale can be found here. 23.28% of the stock is currently owned by corporate insiders.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Read More: How Do Investors Open a Backdoor Roth IRA?
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.